A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors

Exclusion Criteria

• •Hematologic malignancy has or is suspected to involve the central nervous system, or primary central nervous system lymphoma;
• •Received any anti-cancer therapy such as major surgery, chemotherapy and/or radiotherapy, immunotherapy, or targeted therapy within 4 weeks prior to the first dose;
• •Combined with severe or not well-controlled diseases, which the investigator judges to be at greater risk of entering this study；
• •Those with a history of drug addiction or substance abuse；
• •Based on the investigator's judgement, subjects with concomitant diseases that pose a significant risk to their safety or compromise the study's completion, or subjects deemed unsuitable for enrollment due to other reasons, will be excluded.